XJPX
2934
Market cap40mUSD
Dec 05, Last price
1,330.00JPY
1D
-0.82%
1Q
-29.78%
IPO
-66.92%
Name
J Frontier Co Ltd
Chart & Performance
P/E
71.26
P/S
0.29
EPS
18.66
Div Yield, %
—
Shrs. gr., 5y
2.10%
Rev. gr., 5y
24.79%
Revenues
21.50b
+21.39%
Net income
88m
P
CFO
509m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
J Frontier Co.,Ltd. engages in the healthcare sale, medical care sale, and healthcare marketing businesses in Japan. It is involved in various activities, including online medical care, medication guidance, as well as operates drug delivery platform, medical institutions, and operates dispensing pharmacy. The company engages in distribution of pharmaceuticals products as well as involved in marketing, logistics, and call center activities. J Frontier Co.,Ltd. was incorporated in 2008 and is based in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑05 | 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||